InvestorsHub Logo
Followers 46
Posts 2450
Boards Moderated 0
Alias Born 04/17/2019

Re: Rockleo post# 131307

Thursday, 12/03/2020 8:17:03 AM

Thursday, December 03, 2020 8:17:03 AM

Post# of 232944
The problem I could see with that approach is there was no baseline so no way to see progression. The second problem is that the number of patients is too small to do a comparative study. If none ot a very small number of patients had NASH you could infer it was due to leronlimab but that won't impress the FDA.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News